COR Q2 2026 Earnings Call Summary

Cencora Inc. Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Adjusted Diluted EPS: $4.75, up 7.5% year-over-year.
Consolidated Revenue: $78.4 billion, a 4% increase.
Consolidated Gross Profit: $3.4 billion, up 16%, with a gross profit margin of 4.31%, an increase of 45 basis points.
Consolidated Operating Income: $1.3 billion, a 6% increase.
U.S. Healthcare Solutions Revenue: $68.8 billion, up 3%.
International Healthcare Solutions Revenue: $7.6 billion, up 13% (7% on a constant currency basis).
Cash Balance: $2.2 billion, with $1.1 billion in free cash flow generated in the quarter.

2. Strategic Updates and Business Highlights

Cencora resumed opportunistic share repurchases, planning to buy back $1 billion worth of shares by year-end.
Focus on digital transformation and enhancing the pharmaceutical supply chain, including AI-supported tools for customer support.
Continued investment in specialty pharmaceuticals, with growth in areas like cell and gene therapies.
Successful integration of OneOncology, with joint teams established to share best practices and drive growth across platforms.
Positive trends in the International Healthcare Solutions segment, particularly in European distribution and specialty logistics.

3. Forward Guidance and Outlook

Adjusted EPS Guidance: Raised to $17.65 - $17.90, up from $17.45 - $17.75.
Revenue Growth Guidance: Adjusted to 4% - 6%, down from 7% - 9%, primarily due to lower expectations for U.S. Healthcare Solutions and GLP-1 growth.
Operating Income Growth Guidance: Increased to 12% - 14%, up from 11.5% - 13.5%.
Anticipated stronger growth in the fourth quarter as the company laps the loss of the oncology customer and benefits from OneOncology's contributions.

4. Bad News, Challenges, or Points of Concern

Revenue growth in U.S. Healthcare Solutions was tempered by:
- $2 billion impact from manufacturer list price reductions.
- Loss of an oncology customer and a grocery customer.
- Faster-than-expected brand conversions at a large mail order pharmacy customer, leading to lower-margin sales.
Operating expenses rose 22.5%, largely due to the OneOncology acquisition, with core expenses expected to moderate in the second half of the year.
Weather-related disruptions led to a $10 million headwind in operating income, and COVID-19 vaccine revenues decreased, impacting year-over-year comparisons.

5. Notable Q&A Insights

Management expressed confidence in maintaining operating income growth despite revenue pressures from biosimilars and price reductions.
The speed of brand conversions to biosimilars was noted as faster than anticipated, impacting revenue but not significantly affecting operating income.
Concerns were raised about the long-term impact of increasing generics and biosimilars on profit pools, particularly in the specialty market.
Management highlighted that while there are revenue pressures, they expect to maintain margins through the value of their services and infrastructure.
The integration of OneOncology is progressing well, with expectations for significant contributions to growth moving forward.

Overall, Cencora's Q2 2026 results reflect resilience and strategic focus, with positive growth in adjusted EPS and operating income, though tempered by external challenges and adjustments in revenue guidance.

COR — Cencora, Inc.